SCHEMBL5879189

SCHEMBL5879189

Cc1cccc2c(C3=CC(=O)NC3=O)c[nH]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 9/20 0.46
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
BRPF1 P55201 1/20 0.44
PRKCB P05771 1/20 0.43
PRKCA P17252 1/20 0.43
PRKCH P24723 1/20 0.43
PRKCE Q02156 1/20 0.43
PRKCQ Q04759 1/20 0.43
PRKCD Q05655 1/20 0.43
NR4A2 P43354 1/20 0.41
HTR2A P28223 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SOS2 Q07890 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879156 0.82 AR (0.45) ARPRKCBPRKCAPRKCHPRKCE
SCHEMBL5879217 0.82 CLK1 (0.43) ARPRKCBPRKCAPRKCHPRKCE
SCHEMBL5879128 0.82 KDM4E (0.48) ARHTR2AKDM4EMAPTSMN1; SMN2
SCHEMBL9374514 0.81 PRKCB (0.57) ARTRIM24TRIM33BRPF1PRKCB
SCHEMBL711313 0.77 DAO (0.43) KDM4EMAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL5879276 0.77 GPR84 (0.44) PRKCBPRKCAPRKCHPRKCEPRKCQ
Ammonia Solution, Strong SCHEMBL27993531 0.76 DAO (0.42) KDM4E
SCHEMBL2193383 0.75 PRKCB (0.65) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL29771997 0.75 PRKCB (0.65) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL1050913 0.75 GSK3B (0.41) PRKCBPRKCAPRKCHPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 AR 617/4885TRIM24 1309/4885TRIM33 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.